# A Phase 2 Study of Firi-cel in Patients With Relapsed/Refractory Large B-cell Lymphoma

> **NCT05972720** · PHASE2 · TERMINATED · sponsor: **CARGO Therapeutics** · enrollment: 101 (actual)

## Conditions studied

- Cancer
- Relapsed/Refractory Large B-cell Lymphoma (LBCL)

## Interventions

- **DRUG:** Fludarabine (Conditional therapy)
- **DRUG:** Cyclophosphamide Monohydrate (Conditional therapy)
- **DRUG:** firi-cel (Experimental drug)

## Key facts

- **NCT ID:** NCT05972720
- **Lead sponsor:** CARGO Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-08-01
- **Primary completion:** 2025-04-04
- **Final completion:** 2025-04-04
- **Target enrollment:** 101 (ACTUAL)
- **Why stopped:** Company decision to stop trial, withdraw the IND and close down operations.
- **Last updated:** 2025-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05972720

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05972720, "A Phase 2 Study of Firi-cel in Patients With Relapsed/Refractory Large B-cell Lymphoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05972720. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*